SynthesisFrontiers in oncology2021

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.

Ning Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.